Oct 28, 2025 6:01 AM Eastern Daylight Time BeOne Medicines to Present at Upcoming Investor Conferences Share SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: Live webcasts of these events can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beon ...

公司动态 - 公司BeOne Medicines Ltd宣布其下一代BCL2抑制剂sonrotoclax获得美国FDA突破性疗法认定 用于治疗复发或难治性套细胞淋巴瘤成人患者 [1] - 公司是一家全球性肿瘤公司 在纳斯达克、香港联交所和上海证券交易所上市 [1] 产品研发 - 公司研发的sonrotoclax是一种下一代研究性BCL2抑制剂 有潜力成为同类最佳药物 [1] - sonrotoclax的突破性疗法认定针对的适应症为复发或难治性套细胞淋巴瘤 [1]